Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Beigene Ltd (BGNE)  
$162.58 3.80 (2.28%) as of 4:30 Fri 6/14


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 90,630,000
Market Cap: 14.73(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $129.52 - $225.13
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  664
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 50,000 100,397 1,205,681 5,584,204
Total Sell Value $7,475,024 $15,909,372 $215,448,356 $1,085,316,909
Total People Sold 1 2 7 9
Total Sell Transactions 3 6 13 52
End Date 2024-03-17 2023-12-15 2023-06-16 2022-06-16

   
Records found: 527
  Page 21 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Glazer Donald W. Director   –       •      –    2016-09-22 4 AS $31.13 $778,561 I/I (25,010) 100,045     -
   Glazer Donald W. Director   –       •      –    2016-09-21 4 AS $31.19 $508,958 I/I (16,318) 125,055     -
   Glazer Donald W. Director   –       •      –    2016-09-20 4 AS $31.01 $255,615 I/I (8,243) 141,373     -
   Glazer Donald W. Director   –       •      –    2016-09-19 4 AS $31.56 $1,348,487 I/I (42,691) 149,616     -
   Huang Jane CMO, Hematology   •       –      –    2016-09-02 4 A $0.00 $0 D/D 300,000 300,000     -
   Peterson Amy C. CMO, Immuno-oncology   •       –      –    2016-08-22 4 A $0.00 $0 D/D 300,000 300,000     -
   Glazer Donald W. Director   –       •      –    2016-07-14 4 GD $0.00 $0 D/D 3 4,881,997     -
   Glazer Donald W. Director   –       •      –    2016-07-07 4 GD $0.00 $0 D/D 250,000 4,882,000     -
   Li Ji EVP and Gl. Head of Bus. Dev.   •       –      –    2016-05-03 4 A $0.00 $0 D/D 475,000 475,000     -
   Merck Sharp & Dohme Research Gmbh 10% Owner   –       –       •   2016-02-08 4 A $0.00 $0 I/I 7,942,314 7,942,314     -
   Merck Sharp & Dohme Research Gmbh 10% Owner   –       –       •   2016-02-08 4 A $0.00 $0 I/I 23,646,724 5,128,205     -
   Hillhouse Capital Management, Ltd. 10% Owner   –       –       •   2016-02-08 4 B $0.00 $0 I/I 9,100,000 39,726,779 1.42     -
   Hillhouse Capital Management, Ltd. 10% Owner   –       –       •   2016-02-08 4 A $0.00 $0 I/I 30,626,779 30,626,779     -
   14159, L.p. Director   –       •       •   2016-02-08 4 B $24.00 $45,904,320 I/I 1,912,680 1,723,306 2.25     -
   14159, L.p. Director   –       •       •   2016-02-08 4 OE $0.68 $1,750,000 I/I 2,592,593 639,600     -
   14159, L.p. Director   –       •       •   2016-02-08 4 A $0.00 $0 I/I 77,742,164 70,865,132     -
   Wang Xiaodong Director   –       •      –    2016-02-08 3 IO $0.00 $0 I/I 0 214,531     -
   Wang Xiaodong Director   –       •      –    2016-02-08 3 IO $0.00 $0 D/D 0 16,344,143     -
   Oyler John CEO   •       •       •   2016-02-08 4 A $0.00 $0 D/D 9,398,380 59,780,349     -
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2016-02-08 4 B $1.85 $120,250 D/D 65,000 65,000 2.74     -
   Citic Pe Funds Ltd 10% Owner   –       –       •   2016-02-08 4 A $0.00 $0 D/D 19,601,138 19,601,138     -
   Yuan Ruirong Chief Medical Officer   •       –      –    2016-02-08 4 B $1.85 $240,500 D/D 130,000 130,000 2.74     -
   Oyler John Chief Executive OfficeOfficer   •       •       •   2016-02-02 3 IO $0.00 $0 I/I 0 18,102,188     -
   Oyler John Chief Executive OfficeOfficer   •       •       •   2016-02-02 3 IO $0.00 $0 D/D 0 50,381,969     -
   Glazer Donald W. Director   –       •      –    2016-02-02 3 IO $0.00 $0 I/I 0 2,500,000     -

  527 Records found
  Previous  20  21  22   
  Page 21 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed